nih national institutes of health

NIH Director Bhattacharya to Temporarily Run CDC

NIH Director Jay Bhattacharya to take over as temporary CDC chief: media reports

Debra Houry, M.D., a former chief medical officer at the CDC who departed in August, told the NYT that while the CDC and the NIH do have programs they work on together, the agencies "have a fundamentally different approach" in their work.

· 19h · on MSN

NIH director Jay Bhattacharya will take over leadership of CDC temporarily

· 17h

NIH director Dr. Jay Bhattacharya to take over as acting head of CDC

· 17h

NIH’s Bhattacharya will also run the CDC while Trump administration looks for a permanent director

National Institutes of Health Director Jay Bhattacharya will also temporarily become acting director of the Centers for Disease Control and Prevention, an administration official said Wednesday.

· 18h

RFK Jr. Continues Leadership Shake-Up, Placing Top Lieutenant in Charge of CDC

· 20h

N.I.H. Director Will Temporarily Run C.D.C. in Leadership Shake-Up

1don MSN

National Institutes of Health faces leadership vacuum as director positions sit open

More than half of the National Institutes of Health's 27 institutes and centers are missing permanent directors, giving the Trump administration an unusual opportunity to reshape NIH.

Inside Higher Ed

NIH Director Will Be Acting CDC Chief; O’Neill to Be Nominated NSF Director

The official said NIH director Jay Bhattacharya will maintain his current duties while also leading the CDC “until a permanent CDC director is nominated and confirmed.” Jim O’Neill was dismissed last week from leading the CDC,

22h

NIH Institute Told To Drop ‘Biodefense’ and 'Pandemic Preparedness' Language From Website

WEDNESDAY, Feb. 18, 2026 (HealthDay News) — As new infectious threats emerge worldwide, a key U.S. health agency is quietly stepping away from language tied to pandemic planning, a change some experts warn could leave Americans less protected when the next crisis hits.

Bisnow

Reversal Of NIH Funding Cuts Preserves Pipeline Of Potential Biotech Tenants

A reversal of cuts to the National Institutes of Health budget has life sciences operators breathing a sigh of relief.

6don MSN

NIH stops Johnson & Johnson's blood thinner drug arm in stroke trial after safety review (updated)

Editor’s Note: The story has been updated with comments from J&J The National Institutes of Health (NIH) on Tuesday discontinued the low-dose rivaroxaban arm of its ongoing Phase 3 CAPTIVA stroke prevention trial.